Internet-based Mindfulness and Exposure Treatment for Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

Internet-based Mindfulness and Exposure Treatment for Atopic Dermatitis: Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03051958
• Other study ID #: ICBT atopic dermatitis
• Status: Completed
• Phase: N/A
• Start date: March 29, 2017
• Est. completion date: June 28, 2019

Study information

• Verified date: March 2021
• Source: Karolinska Institutet
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Atopic dermatitis (AD) is highly prevalent and leads to suffering for the individual, increased risk of depressive symptoms and anxiety, and high societal costs. A few psychological treatment have been tested for AD, but to our knowledge none of them have been built on recently developed methods for optimizing exposure treatment. In addition, access to psychological treatment is limited and there is a need for new methods that could be easily disseminated. One possible solution to this problem is to deliver psychological treatment via the Internet, which has been tested in more than 100 randomized trials with good results for other clinical disorders than AD. The aim of this study was to test the effects of Internet-delivered mindfulness and exposure treatment (I-MET) for AD in a randomized controlled trial. We hypothesized that I-MET would lead to larger reductions of AD symptoms as well as psychological symptoms compared to treatment as usual.

Description:

Atopic dermatitis (AD), characterized by chronic itching and inflammation, is highly prevalent and leads to suffering for the individual, increased risk of depressive symptoms and anxiety, and high societal costs. Several behavioral factors are likely to play a role in the exacerbating AD symptoms over time, not least scratching, which may lead to rupture in the skin barrier and an increased risk of inflammation, which in turns increases AD symptoms. AD is also associated with avoidance behaviors that may have negative longer-term effects. With this in mind, psychological treatment based on exposure may be a logical method to achieve improvements. A few psychological treatments have been tested for AD, but to our knowledge none of them have been built on recently developed methods for optimizing exposure treatment. In a recently conducted pilot study we showed that exposure treatment, in combination with mindfulness training, can be associated with improvements for persons with AD. One challenge regarding psychological treatment is that accessibility is limited and there is a need for new methods that could be easily disseminated. One possible solution to this problem is to deliver psychological treatment via the Internet, which has been tested in more than 100 randomized trials with good results for other clinical disorders than AD. Internet-based treatment can be described as a form of online bibliotherapy where the individual is guided by a therapist who provides feedback on homework assignments. The aim of this study was to test the effects of Internet-delivered mindfulness and exposure treatment (I-MET) for AD in a randomized controlled trial. We hypothesized that I-MET would lead to larger reductions of AD symptoms as well perceived stress, sleep problems, depressive symptoms, general anxiety, and improved self-rated health, compared to treatment as usual.

CLARIFICATION REGARDING STUDY START DATE (remark made on March 15, 2021): This trial employed one informed consent which was completed before the provision of screening data for the purpose of assessing eligibility. The first date on which a participant provided informed consent and screening data was Nov 27, 2016. The first date a participant was included in the study, as based on the assessment of eligibility criteria in accordance with the study protocol, was March 29, 2017. The latter date is considered to be the study start date, in accordance with 81 FR 65022.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 102
• Est. completion date: June 28, 2019
• Est. primary completion date: June 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Fulfills the diagnostic criteria for atopic dermatitis in accordance with Williams criteria 1994

• at the time of inclusion the eczema should be at least moderate according to The Patient Oriented Eczema Measure (POEM)

• Regular access to computer and internet connection

• If on antidepressant or regular sleep medication, the medication should be stable for at least one month prior to inclusion and the person should be willing to keep the medication stable throughout the study

• possibility to actively carry out the treatment (not go for longer journeys, do homework)

• good understanding of written and spoken Swedish

Exclusion Criteria:

• severe psychiatric illness (bipolar disorder, schizophrenia or other psychotic illness, substance, alcohol abuse, severe depression, suicide risk)

• difficulties with reading or writing

• ongoing treatment for cancer

• pregnancy

• other psychological treatment that i ongoing or recently terminated

• stronger anxiety-reducing medication such as benzodiazepines

• treatment with antibiotics that is ongoing or has been terminated less than one month prior to inclusion

• Psoriasis

• UV-light treatment that is ongoing or has been terminated less than one month prior to inclusion

• oral treatment for eczema that is ongoing or has been terminated less than two month prior to inclusion

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Behavioral:
• Internet mindfulness&exposure treatment
See description under "Arm".

Other:
• Treatment as usual
Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.

Locations

Country	Name	City	State
Sweden	Karolinska Institutet	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Client Satisfaction Questionnaire (CSQ-8)	Mean and standard deviations will be presented	Post-treatment (12)
Other	Alcohol Disorders Identification Test (AUDIT)	This measure is used only as a mean for gathering data regarding inclusion/exclusion criteria	Baseline
Other	Drug Use Disorders Identification Test (DUDIT)	This measure is used only as a mean for gathering data regarding inclusion/exclusion criteria	Baseline
Other	Mediators using: Pain Reactivity Scale, Psychological Inflexibility in Pain Scale, Five Facets of Mindfulness- non reactivity scale, visual analogue scales for (itch, scratching and insomnia), and use of antiinflammatory skin creme	Change in mediators from baseline to post-treatment (12 weeks) will be correlated with change in the primary outcome during the same time period	baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, post-treatment (12 weeks)
Primary	Patient-Oriented Eczema Measure (POEM)	Change in POEM at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, post-treatment (12 weeks) , 6 month follow-up, 12 month follow-up
Secondary	Visual analogue scale itch (VAS-itch)	Change in VAS-scratch at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, post-treatment (12 weeks), weekly during treatment, 6 month follow-up, 12 month follow-up
Secondary	Visual analogue scale scratch (VAS-scratch)	Change in VAS-scratch at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	Visual analogue scale sleep (VAS-sleep)	Change in VAS-sleep at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	Dermatology Quality of Life Index (DLQI)	Change in DLQI at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	Beck Anxiety Inventory (BAI)	Change in BAI at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	Patient Health Questionnaire-9 (PHQ-9)	Change in PHQ-9 at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	Perceived stress scale (PSS)	Change in PSS at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	5-dimensions itch scale (5-D itch scale)	Change in 5-D itch scale at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	Insomnia Severity Index (ISI)	Change in ISI at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	Self-Rated Health (SRH-5)	Change in SRH-5 at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	Brunnsviken Brief Quality of life scale (BBQ)	Change in BBQ at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	EuroQoL-5 Dimension Questionnaire (EQ-5D)	Change in EQ5D at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up
Secondary	The Trimbos and Institute for Medical Technology Assessment Questionnaire on Costs Associated with Psychiatric Illness (TIC-P)	Change in TIC-P at post-treatment and 6 and 12 month follow-ups compared to baseline	baseline, post-treatment (12 weeks), 6 month follow-up, 12 month follow-up